Patient characteristics |
Race | | | | | | | <0.001 | | |
Black | 66 | (17.7) | 44 | (8.2) | 4 | (6.3) | | 114 | (11.7) |
All other | 307 | (82.3) | 491 | (91.8) | 59 | (93.7) | | 857 | (88.3) |
Positive family history | | | | | | | 0.685 | | |
No | 347 | (93.0) | 504 | (94.2) | 60 | (95.2) | | 911 | (93.8) |
Yes | 26 | (7.0) | 31 | (5.8) | 3 | (4.8) | | 60 | (6.2) |
Charlson Comorbidity Index | | | | | | | 0.210 | | |
0 | 103 | (27.6) | 139 | (26.0) | 16 | (25.4) | | 258 | (26.6) |
1 | 118 | (31.6) | 166 | (31.0) | 12 | (19.0) | | 296 | (30.5) |
2 | 79 | (21.2) | 106 | (19.8) | 20 | (31.7) | | 205 | (21.1) |
3+ | 73 | (19.6) | 124 | (23.2) | 15 | (23.8) | | 212 | (21.8) |
Tumor characteristics |
Screen-detected cancer | | | | | | | 0.065 | | |
No | 163 | (48.8) | 275 | (56.9) | 34 | (56.7) | | 472 | (53.8) |
Yes | 171 | (51.2) | 208 | (43.1) | 26 | (43.3) | | 405 | (46.2) |
Baseline PSA (µg/l) | | | | | | | 0.009 | | |
0 to <4.0 | 65 | (17.4) | 65 | (12.1) | 3 | (4.8) | | 133 | (13.7) |
4.0 to <10.0 | 125 | (33.5) | 179 | (33.5) | 17 | (27.0) | | 321 | (33.1) |
10.0 to <20.0 | 85 | (22.8) | 136 | (25.4) | 14 | (22.2) | | 235 | (24.2) |
≥20.0 | 98 | (26.3) | 155 | (29.0) | 29 | (46.0) | | 282 | (29.0) |
Histology (Gleason score) |
Good (2–4) | 81 | (21.7) | 107 | (20.0) | 7 | (11.1) | 0.049 | 195 | (20.1) |
Moderate (5–7) | 226 | (60.6) | 333 | (62.2) | 36 | (57.1) | | 595 | (61.3) |
Poor (8–10) | 66 | (17.7) | 95 | (17.8) | 20 | (31.7) | | 181 | (18.6) |
Anatomic stage | | | | | | | 0.317 | | |
Local | 329 | (88.2) | 463 | (86.5) | 53 | (84.1) | | 845 | (87.0) |
Regional | 23 | (6.2) | 34 | (6.4) | 2 | (3.2) | | 59 | (6.1) |
Metastatic | 21 | (5.6) | 38 | (7.1) | 8 | (12.7) | | 67 | (6.9) |
Molecular marker status |
Bcl-2 | | | | | | | 0.072 | | |
Negative | 330 | (94.3) | 458 | (92.2) | 49 | (86.0) | | 837 | (92.6) |
Positive | 20 | (5.7) | 39 | (7.8) | 8 | (14.0) | | 67 | (7.4) |
p53 | | | | | | | 0.004 | | |
Negative | 273 | (75.6) | 387 | (74.9) | 34 | (55.7) | | 694 | (73.9) |
Positive | 88 | (24.4) | 130 | (25.1) | 27 | (44.3) | | 245 | (26.1) |
Microvessel density | | | | | | | 0.016 | | |
<29 vessels/HPF | 170 | (49.0) | 236 | (47.0) | 17 | (28.8) | | 423 | (46.6) |
≥29 vessels/HPF | 177 | (51.0) | 266 | (53.0) | 42 | (71.2) | | 485 | (53.4) |
Treatment and outcomes |
Initial treatment | | | | | | | <0.001 | | |
Watchful waiting or none | 61 | (16.4) | 172 | (32.1) | 24 | (38.1) | | 257 | (26.5) |
External beam/seed XRT | 128 | (34.3) | 204 | (38.1) | 13 | (20.6) | | 345 | (35.5) |
Androgen deprivation only | 52 | (13.9) | 116 | (21.7) | 26 | (41.3) | | 194 | (20.0) |
Prostatectomy | 132 | (35.4) | 43 | (8.0) | 0 | (0.0) | | 175 | (18.0) |
Cancer-specific mortality | | | | | | | 0.011 | | |
No | 318 | (85.3) | 439 | (82.1) | 44 | (69.8) | | 801 | (82.5) |
Yes | 55 | (14.7) | 96 | (17.9) | 19 | (30.2) | | 170 | (17.5) |
All-cause mortality | | | | | | | <0.001 | | |
No | 148 | (39.7) | 112 | (20.9) | 3 | (4.8) | | 263 | (27.1) |
Yes | 225 | (60.3) | 423 | (79.1) | 60 | (95.2) | | 708 | (72.9) |